96 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22773 | after two lines, RECIST 1.1 | Ahmad Hussein Awada | Breast | Nektar Therapeutics | IJB_2655 | Trial closed | A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine | ahmad.awada@hubruxelles.be | 3 | 3 | |
| 22650 | vaccine, diarrhea, clostridium | Multiple | Pfizer | IJB_2672 | Trial closed | A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | 3 | 3 | |||
| 22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention | |||||
| 22657 | Metastatic, Biopsy mandatory | Nuria Kotecki | Multiple | Lilly | IJB_2732 | Trial closed | A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors | Nuria.Kotecki@hubruxelles.be | 1/1b | 1 | |
| 22633 | Metastatic, first line, RECIST 1.1 | Philippe Aftimos | Breast | Servier | IJB_2743 | Trial closed | Phase I/II trial of S81694 administered intravenously in combination with paclitaxel to evaluate the safety, pharmacokinetic and efficacy in metastatic breast cancer | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 22735 | No contraindication for immunotherapy | Laurence Buisseret | Breast | Institut Jules Bordet | IJB-LBC-NEOCHECKRAY-2018 | Trial closed for recruitment | Neo-adjuvant chemotherapy combined with SBRT to the primary tumor +/- durvalumab +/- oleclumab in luminal B breast cancer: a phase ll randomized trial | laurence.buisseret@hubruxelles.be | 2 | 2 | |
| 22705 | Metastatic. ER-/PR-/HER2- | Philippe Aftimos | Breast | Institut Jules Bordet | IJB-SYNERGY-012017 | Trial closed for recruitment | A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer. Synergy Trial (IJB-SYNERGY-012017) | philippe.aftimos@hubruxelles.be | 1/2 | 1 | |
| 22720 | Participated in parent study | Thierry Berghmans | Multiple | Roche | IMBrella | Trial closed for recruitment | An open label, multicenter extension study in patients previously enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B) | 4 | 4 | ||
| 22734 | HR+/HER2- | Philippe Aftimos | Breast | Immunomedics | IMMU-132-09 | Trial closed for recruitment | Phase 3 Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens | philippe.aftimos@hubruxelles.be | 3 | 3 | |
| 28538 | Philippe Aftimos | Breast | Immunomedics | IMMU-132-14 | Trial closed for recruitment | Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan | philippe.aftimos@hubruxelles.be | 3 | 3 | ||
| 22683 | Non-metastatic operable. TNBC. Adjuvant. Atezolizumab | Michail Ignatiadis | Breast | Roche | IMpassion 030 (BIG 16-05/AFT-27/WO39391) | Trial closed | A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer | michail.ignatiadis@hubruxelles.be | 3 | 3 | |
| 22662 | second line, RECIST 1.1, Biopsy | Philippe Aftimos | Multiple | Incyte Corporate | INCAGN1876-201 | Trial closed | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 22640 | Metastatic, Biopsy mandatory | Christiane Jungels | Multiple | Incyte Corporate | INCB 01158-203 | Trial closed | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors. (INCB01158-203) | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22655 | Any line | Ahmad Hussein Awada | Solid tumors | Incyte Corporate | INCB59872-101 | Trial closed | A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies | ahmad.awada@hubruxelles.be | 1/2 | 1 |